Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
It’s an exciting time for research into microbiome therapeutics. This can be seen in the explosion of new clinical studies in the field, which, […]
A gut check on microbiome therapeutics development Read More »
Nearly 16 million Americans are taking care of someone with Alzheimer’s disease – and the cost of caring for someone with the disease goes
Tackling Alzheimer’s requires cooperation, access, and broad and equitable coverage Read More »
There are more barriers between patients and the medications that they need than price, agreed experts at the BIO International Convention in June 2022.
How to overcome non-price barriers to patient access to medical care, drugs Read More »
Growing vegetables in space is no longer sci-fi, but rather fully possible, according to The Conversation. As climate change is affecting our capacity to
Biotech can help us grow veggies in space Read More »
More than two years on from COVID, offices and the world of work remain forever changed. Many companies are offering hybrid work models, where
How biotech recruiting has changed in the post-COVID world Read More »
The journey of the data point is no longer linear, as advanced digital innovations are now employed throughout all the phases of drug development,
The data point is no longer linear, say data scientists Read More »
Thanks to gene therapies, previously untreatable diseases are now treatable and patient quality of life has improved exponentially. Yet, gene therapy regulatory challenges, along
How gene therapy regulatory challenges impact R&D, manufacturing, patients Read More »
John Trizzino, Executive Vice President, Chief Commercial Officer, and Chief Business Officer of Novavax, joined Good Day BIO Live at the BIO International Convention,
Vaccine in 100 days ‘extraordinarily possible,’ says John Trizzino of Novavax Read More »
Misinformation. Not COVID. Not heart disease. Not cancer. Misinformation. That’s what the Commissioner of the U.S. Food and Drug Administration recently declared the leading
BIO Board Member: Biotech’s voice needs to get louder – and clearer Read More »
The FDA’s Accelerated Approval pathway has assisted America’s biotech industry in making remarkable advances over the last 30 years—but it has come under political
Accelerated Approval is under political attack, experts say Read More »
